24/05/2021 — Laevoroc Oncology Launches With Three-Pronged Strategy

In Vivo interview with our CEO, Thomas Mehrling, where he presented Laevoroc Oncology’s three-pronged strategy to off-set risk and provide greater choice to future partners in supporting Laevoroc’s development of game-changing oncology medicines.

Read the full article here.